Delineating antibody recognition against Zika virus during natural infection

Journal of Clinical Investigation

Volumn 2, Issue 12, 2017, Pages

  Yu, Lei ^a   Wang, Ruoke ^b   Gao, Fei ^b   Li, Min ^c   Liu, Jianying ^b   Wang, Jian ^a   Hong, Wenxin ^a   Zhao, Lingzhai ^a   Wen, Yingfen ^a   Yin, Chibiao ^a   Wang, Hua ^b   Zhang, Qi ^b   Li, Yangyang ^b   Zhou, Panpan ^b   Zhang, Rudian ^b   Liu, Yang ^b   Tang, Xiaoping ^a   Guan, Yongjun ^a   Qin, Cheng Feng ^d   Chen, Ling ^a,e   Shi, Xuanling ^b   Jin, Xia ^c   Cheng, Gong ^b   Zhang, Fuchun ^a   Zhang, Linqi ^b   more..

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Tsinghua University   (China)

^c INSTITUTE PASTEUR OF SHANGHAI   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85040226711     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/jci.insight.93042     Document Type: Article

References (54)

1. Brasil P, et al. Guillain-Barré syndrome associated with Zika virus infection. Lancet. 2016;387(10026):1482.
2. Cao-Lormeau VM, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387 (10027):1531-1539.
3. Kleber de Oliveira W, et al. Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy - Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65 (9):242-247.
4. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and Birth Defects-Reviewing the Evidence for Causality. N Engl J Med. 2016;374(20):1981-1987.
5. Mlakar J, et al. Zika Virus Associated with Microcephaly. N Engl J Med. 2016;374(10):951-958.
6. Oehler E, et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill. 2014;19 (9):20720.
7. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509-520.
8. Faria NR, et al. Zika virus in the Americas: Early epidemiological and genetic findings. Science. 2016;352 (6283):345-349.
9. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis. 2016;16(7):e119-e126.
10. Singer M. The spread of Zika and the potential for global arbovirus syndemics. Glob Public Health. 2017;12 (1):1-18.
11. Voss A, Kluytmans J, Pittet D. A new journal and new global perspective on infection control and public health. Antimicrob Resist Infect Control. 2012;1 (1):4.
12. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31:705-742.
13. Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol. 2016;34:635-659.
14. Pierson TC, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1 (2):135-145.
15. Beltramello M, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8 (3):271-283.
16. Barba-Spaeth G, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48-53.
17. Zhao H, et al. Structural Basis of Zika Virus-Specific Antibody Protection. Cell. 2016;166(4):1016-1027.
18. Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3(12):2374-2395.
19. Dejnirattisai W, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170-177.
20. Fibriansah G, Lok SM. The development of therapeutic antibodies against dengue virus. Antiviral Res. 2016;128:7-19.
21. Sirohi D, et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science. 2016;352 (6284):467-470.
22. Kostyuchenko VA, et al. Structure of the thermally stable Zika virus. Nature. 2016;533 (7603):425-428.
23. Zhang X, et al. Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat Struct Mol Biol. 2013;20(1):105-110.
24. Pierson TC, Diamond MS. Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol. 2012;2 (2):168-175.
25. Zhang Y, et al. Conformational changes of the flavivirus E glycoprotein. Structure. 2004;12 (9):1607-1618.
26. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ. Structure of West Nile virus. Science. 2003;302(5643):248.
27. Kuhn RJ, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108 (5):717-725.
28. Dai L, et al. Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host Microbe. 2016;19 (5):696-704.
29. Kaufmann B, et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci USA. 2010;107 (44):18950-18955.
30. Sapparapu G, et al. Neutralizing human antibodies prevent Zika virus replication fetal disease in mice. Nature. 2016;540(7633):443-447.
31. Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353 (6301):823-826.
32. Wang Q, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med. 2016;8 (369):369ra179.
33. Rouvinski A, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015;520 (7545):109-113.
34. Austin SK, Dowd KA. B cell response and mechanisms of antibody protection to West Nile virus. Viruses. 2014;6(3):1015-1036.
35. Zhang FC, Li XF, Deng YQ, Tong YG, Qin CF. Excretion of infectious Zika virus in urine. Lancet Infect Dis. 2016;16(6):641-642.
36. Sukupolvi-Petty S, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81 (23):12816-12826.
37. Zuo T, et al. Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. Nat Commun. 2015;6:8855.
38. Zuo T, et al. Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast. J Biol Chem. 2011;286 (38):33511-33519.
39. Smith SA, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio. 2013;4 (6):e00873-e00813.
40. Liu J, et al. Flavivirus NS1 protein in infected host sera enhances viral acquisition by mosquitoes. Nat Microbiol. 2016;1 (9):16087.
41. Orozco S, et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol. 2012;93 (Pt 10):2152-2157.
42. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30-50.
43. Priyamvada L, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA. 2016;113(28):7852-7857.
44. Imrie A, et al. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 2007;20 (4):672-675.
45. Dejnirattisai W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17 (9):1102-1108.
46. Swanstrom JA, et al. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. MBio. 2016;7(4):e01123.
47. Chan KR, et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA. 2011;108 (30):12479-12484.
48. Kam YW, et al. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight. 2017;2(8):e92428.
49. Dejnirattisai W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328 (5979):745-748.
50. Bardina SV, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356(6334):175-180.
51. Zhang Y, et al. Highly diversified Zika viruses imported to China, 2016. Protein Cell. 2016;7 (6):461-464.
52. Guan Y, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci USA. 2009;106(10):3952-3957.
53. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. 2008;329 (1-2):112-124.
54. Jiang L, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6 (234):234ra59.